课题基金 / 基金详情

Exploiting the Unique T Cell Response to CMV for a Cancer Vaccine

Exploiting the Unique T Cell Response to CMV for a Cancer Vaccine
利用 T 细胞对 CMV 的独特反应来开发癌症疫苗
批准号:
7796744
负责人:
Ann B Hill
金额:
$16.78万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2011-03-31

项目摘要

项目成果

Ann B Hill的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this project is to develop an attenuated cytomegalovirus-based vaccine vector expressing the melanoma antigen trp-1 for use in tumor immunotherapy. Certain features of the immunobiology of CMV suggest that a vaccine based on it could make a unique contribution to the tumor immunotherapy arsenal. It is extraordinarily immunogenic for CD8 T cells; it has been shown to overcome self-tolerance to a tissue specific antigen, and as a vaccine vector it can be used sequentially. However, a live virus has obvious limitations as a vector for immune-compromised tumor patients. We have recently shown that a CMV vector that is completely replication deficient nevertheless establishes latency and can prime the characteristic ongoing massive immune response. The goal of the current project is to develop the replication deficient MCMV strain as a vaccine vector, using the well characterized B16 mouse melanoma model. The majority of the project is devoted to optimizing the immune response that can be elicited by the replication deficient vector. We will compare immunogenicity when the tumor antigen is expressed behind different viral promoters, and determine whether antigen expression and immunogenicity can be enhanced further by the use of adjuvants that drive viral IE gene expression. We will use two measures of vaccine efficacy (a) size of the CD8 T cell response an (b) ability to protect against tumor challenge using B16 cells. PUBLIC HEALTH RELEVANCE: Cytomegalovirus (CMV) infection, which is usually asymptomatic and has been safely used as a vaccine, generates a potent cellular immune response and immunological memory that is maintained for life. Previously, CMV has been engineered to induce the immune system to target normal tissues. Our goal is to harness this potent immune response elicited by CMV to test use as an effective tumor vaccine. A safe vaccine vector that is unable to replicate will be generated for this purpose.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
T cell response to fibroblast-trophic CMV vaccine in humans
T cell response to fibroblast-trophic CMV vaccine in humans
Cytomegalovirus and diseases of aging: a secondary analysis of NHANES III data
Cytomegalovirus and diseases of aging: a secondary analysis of NHANES III data
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究